Caris Life Sciences, Inc. reports results for the quarter ended June 30 - Earnings Summary

Caris Life Sciences

06/08/2026 06:14

Caris Life Sciences, Inc. CAI.OQ reported quarterly breakeven results​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-7.97.  The mean expectation of twelve analysts for the quarter was for earnings of one cent per share. Wall Street expected results to range from -4 cents to 6 cents per share.
Revenue fell 53.6% to $84.12 million from a year ago; analysts expected $238.13 million. 
Caris Life Sciences, Inc.'s reported EPS for the quarter was breakeven results​.
The company reported a quarterly loss of $637 thousand.
Caris Life Sciences, Inc. shares had fallen by 9.7% this quarter and lost 40.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 60.5% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy" 
Wall Street's median 12-month price target for Caris Life Sciences, Inc. is $27.00, about 39.1% above its last closing price of $16.45
This summary was machine generated from LSEG data August 6 at 05:14 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.01
0.00
Missed
Mar. 31 2026 
-0.02
0.00
Beat
Dec. 31 2025 
0.03
0.28
Beat
Sep. 30 2025 
-0.21
0.08
Beat